Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications - Wikidata - wikimedia - TriplyDB

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications

http://www.wikidata.org/entity/Q33621393

about

The efficacy and safety of immunotherapy in patients with advanced NSCLC: a systematic review and meta-analysis.Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.Ipilimumab for the treatment of metastatic prostate cancer.

P2860

Q33434828-C083A33B-44EB-4953-9430-9C64237B0BBC Q33718182-3CB509F6-F8F9-4806-991F-0078592755E4 Q36031597-ED918D0A-7AB2-4598-9EFC-F96BB461CAF5 Q37518336-B157AB6A-A630-4862-B085-164E6F9AC024 Q38264014-6516B16E-B548-4354-9492-8471BF67C971 Q42575268-445BC248-7C31-4F12-A6AE-A3C0B282F575 Q47225399-4981A00F-2C8A-4A7B-BC7E-942C702B7C3B

P2860

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications

http://www.wikidata.org/entity/Q33621393

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Immunotherapy and therapeutic ...... gies and clinical implications

@ast

Immunotherapy and therapeutic ...... gies and clinical implications

@en

type

label

Immunotherapy and therapeutic ...... gies and clinical implications

@ast

Immunotherapy and therapeutic ...... gies and clinical implications

@en

prefLabel

Immunotherapy and therapeutic ...... gies and clinical implications

@ast

Immunotherapy and therapeutic ...... gies and clinical implications

@en

P1433

Q33621393-CCB02BD3-43A3-4D08-91AD-5393B576B029

P1476

Q33621393-54AB8C0E-5AA0-4608-96CF-B206B20E7037

P2093

Q33621393-0F289E2F-0537-4E22-AC70-DDB5E97DE9E8

Q33621393-6B107CA2-6B6B-456C-AFF3-1D84BED66DFE

P275

Q33621393-9CFEB2BA-EAAF-4F30-BA03-E13C83014FD2

P2860

Q33621393-00FA3001-8391-4504-AC4D-BE738168E28C

Q33621393-03FAF0F0-CE32-4B35-80C3-42FC86656957

Q33621393-1AEEF0E5-E386-4315-A578-61BC6B5D4CAB

Q33621393-1B1A6C77-3D6E-49C2-8386-D1454420F82B

Q33621393-20DA60F0-4866-48D3-8FE0-02A2E4D92D86

Q33621393-21F56903-E4BA-44DF-AB12-1DC52890FF98

Q33621393-2CFFA253-3E46-46C4-8F68-EFC736FC318B

Q33621393-2D6D175A-E112-4077-B45E-948E84FB695D

Q33621393-2F03CCB3-0874-45A5-9F47-C3B423600468

Q33621393-324B1AA8-A127-4A80-95BB-2C0B1458F46A

P304

Q33621393-8470EC1A-043A-4FD6-959C-C5163FAC611D

P31

Q33621393-4621A047-8B3D-425B-BC17-2D6BF7F3C404

Q33621393-CA9FCAC8-40BA-4095-91ED-B7990A739AB9

P356

Q33621393-0F7C3048-5B7B-4F7C-8939-4BCDA1F00A31

P433

Q33621393-9FEBA673-ACBE-4B5D-972F-CEB235D6A518

P478

Q33621393-15356CE1-F04D-4028-AA38-DCF655B3AE14

P5008

Q33621393-50CB23B1-805B-4DEF-A942-5D5F1F7BE2E0

P577

Q33621393-91B4F7E3-4770-46D8-A85C-113FAF681D48

P698

Q33621393-CE6454D6-9B6E-445F-95C9-2CE41A92E046

P921

Q33621393-664A37ED-08F3-49F4-A655-8CCFB3528F1A

Q33621393-696C652D-9B3B-47AB-BD17-E5B9E0B8A819

P932

Q33621393-93D9313F-8E6E-4D47-A59B-5928899D98B1

P356

1008-682X.122585

P1433

Asian Journal of Andrology

P1476

Immunotherapy and therapeutic ...... gies and clinical implications

@en

P2093

B Harpreet Singh

http://www.w3.org/2001/XMLSchema#string

James L Gulley

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

P2860

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

P304

364-371

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/1008-682X.122585

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24435055

http://www.w3.org/2001/XMLSchema#string

P921

prostate cancer

P932

4023361

http://www.w3.org/2001/XMLSchema#string